Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer

作     者：Xiao-Dong Li Hua Shen ling-Ting Jiang Han-Ze Zhang Xiao Zheng Yong-Qian Shu Chang-Ping Wu 

作者机构：Department of Oncology the Third Affiliated Hospital of So-ochow University Changzhou 213003 Jiangsu Province China Department of Oncology the FirstAffiliated Hospital of Nanjing Medical University Nanjing210029 Jiangsu Province China Department of Epidemiology and BiostatisticsNanjing Medical University Nanjing 210029 Jiangsu ProvinceChina 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2011年第17卷第8期

页      面：1082-1087页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 100705[医学-微生物与生化药学] 081702[工学-化学工艺] 1002[医学-临床医学] 08[工学] 0817[工学-化学工程与技术] 10[医学] 

基　　金：Supported by The National Natural Science Foundation of China, No. 30872176, 30950022 and 30972703 Jiangsu Province of China, No. K200403 Department of Public Health and Department of Science and Technology (BS2005616) 

主　　题：奥沙利铂 紫杉醇 治疗 胃癌 晚期 基础 VS 醇基 

摘      要：AIM:To compare the efficacy and safety of paclitaxel combined with fluorouracil plus cisplatin(PCF),and oxaliplatin combined with fluorouracil plus leucovorin(FOLFOX-4) regimens for advanced gastric cancer(AGC).METHODS:Ninety-four patients with AGC were randomly assigned to receive paclitaxel(50 mg/m2 iv) on days 1,8 and 15,cisplatin(20 mg/m2 iv) and ? uorouracil(750 mg/m2 iv) on days 1-5,or oxaliplatin(85 mg/m2 iv) and leucovorin(200 mg/m2 iv) on day 1,followed by bolus fluorouracil(400 mg/m2 iv) and fluorouracil(600 mg/m2 iv) on days 1 and *** primary end point was the 1-year survival ***:The overall response rate(ORR) of the pa-tients was 48.0% and 45.5% to PCF and FOLFOX-4,*** disease control rate(DCR) of PCF and FOLFOX-4 was 82.0% and 81.8%,*** median survival times(MSTs) of the patients were 10.8 and 9.9 mo,respectively,after treatment with PCF and *** 1-year survival rate of the patients was 36.0% and 34.1%,respectively,after treatment with PCF and *** significant difference was observed in ORR,DCR,MST or 1-year survival rate between the two *** most common adverse events were anemia,nausea and vomiting,and grade 3/4 alopecia in PCF treatment group,and anemia,grade 1/2 neurotoxic effect and grade 3/4 neutropenia in FOLFOX-4 treatment ***:Patients with AGC have a similar response rate to PCF and FOLFOX-4 regimens with a similar survival *** PCF and FOLFOX-4 regimens are efficacious and tolerable as a promising therapy for AGC.